– USA, MA – X4 Pharmaceuticals, a clinical stage biotechnology company developing novel oral CXCR4 antagonists to improve immune cell trafficking to treat rare disease and certain cancers, today announced the election of Gary J. Bridger, PhD to the company’s Board of Directors. Dr. Bridger was a co-founder and Chief Scientific Officer of AnorMED, Inc., through its acquisition by Genzyme in 2007. Previously, he served as a Board member for Alder Biopharmaceuticals, as Executive Vice President of Research and Development of Xenon Pharmaceuticals, and as Managing Director at Five Corners Capital. Currently, Dr. Bridger is a Board member of Aquinox Pharmaceuticals.
“X4 and its board of directors will benefit from the appointment of Gary Bridger, a well-respected innovator and scientific leader,” said Mike Wyzga, chair of the Board of Directors for X4 Pharmaceuticals. “Gary’s contribution to the high growth and success of many biotechnology companies, including AnorMED, is well recognized. We will leverage Gary’s experience as we execute on our mission to grow X4 into a global commercial organization focused on treatments for rare genetic diseases and certain cancers.”
“X4 is at an exciting moment as we advance X4P-001 into a pivotal trial assessing its potential as the first-ever treatment for WHIM Syndrome, a rare disease of the immune system caused by CXCR4 genetic mutations,” said Paula Ragan, PhD, president and chief executive officer of X4 Pharmaceuticals. “We are fortunate to gain Gary’s strategic insights and expertise given his successful track record of as a leader in the research, development and commercialization of multiple chemokine-targeted therapies, including Mozobil®, an injectable CXCR4 antagonist approved in over 30 countries worldwide.”
“X4’s mission and technology are leading the way for the next generation of chemokine-targeted treatments,” said Dr. Bridger. “I am delighted to apply my experience to help the company realize its goal to make an important impact for patients with rare immune deficiency diseases and certain rare cancers.”
About X4 Pharmaceuticals
X4 Pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer. The Company’s oral small molecule drug candidates antagonize the CXCR4 pathway, which plays a central role in immune surveillance. X4’s most advanced product candidate is in a Phase 2/3 clinical trial in patients with WHIM syndrome, a rare genetic, primary immunodeficiency disease, and is currently under investigation in multiple clinical trials in solid tumors. X4 was founded and is led by a team with deep product development and commercialization expertise, including several former members of the Genzyme leadership team, and is located in Cambridge, MA.
For more information, visit www.x4pharma.com.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.